Cetuximab and irinotecan as third line therapy in patients with advanced colorectal cancer after failure of irinotecan, oxaliplatin and 5-fluorouracil

Prospective analysis of KRAS wild-type patients with metastatic colorectal cancer using cetuximab plus FOLFIRI or FOLFOX4 treatment regimens

“…Furthermore, the PFS/OS of group A was statistically significantly longer than in group B. Our response rate and PFS/OS of group B were compatible with the results of several previous studies from Western countries (Pfeiffer et al, 2007;Martin-Martorell et al, 2008). In group A, the response rate and PFS/OS were similar when compared to the results of several previous studies from Western countries (Folprecht et al, 2006), but were significantly better than group B, and those findings are vital for mCRC patients for the administration of the firstline or second/third-line cetuximab-combination chemotherapy.…”

Current role of antibody therapy in patients with metastatic colorectal cancer

“…The efficacy and toxicity in the first 65 consecutive patients (Pfeiffer et al, 2007b) treated at three departments were registered and it was confirmed in a general population that salvage therapy with Cx and irinotecan is effective in patients pretreated with irinotecan and oxaliplatin. Almost identical results were found in an Italian study with 55 patients (Vincenzi et al, 2006c).…”

“…In BOND I, patients treated with CxIri and developing severe skin rash, RR was 55%, TTP was 8.2 months and median OS was 13.7 months, respectively, and the degree of rash as a predictive marker for RR and OS has been confirmed in many studies (Lenz et al, 2006;Pfeiffer et al, 2007b).…”

Biweekly cetuximab and irinotecan as second-line therapy in patients with gastro-esophageal cancer previously treated with platinum

“…Since 2004, Denmark has had a national health program where non-proven therapy can be offered to patients with advanced cancer, after approval by a Second Opinion Panel appointed by the National Board of Health. This program has had a major impact on the management of cancer patients in Denmark and has accelerated the introduction and implementation of new drugs [16]. Inspired by the high incidence of EGFR over-expression in GEC patients and the promising results seen in patients with mCRC, cetuximab and irinotecan (Cetiri) was administered every second week [17] as experimental second-line therapy in GEC patients whose disease had progressed during or after platinum-based chemotherapy.…”